Should I buy Repligen (RGEN) stock or is it too late?
⭐ The most reliable of them, either direction: Benchmark — 80% of its targets hit on this sector (10 calls tested). It aims for $185 (+1.6 %), call made on July 8, 2026, maturing on July 8, 2027 (51 d ago).
Firm-by-firm track record on Repligen
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Jefferies | 80 % | +69.3 % | 5 | $135 -26% |
| HC Wainwright & Co. | 55 % | +25.6 % | 11 | $208 +14% |
| JP Morgan | 25 % | +0.4 % | 8 | $175 -4% |
| RBC Capital | 20 % | -9.8 % | 10 | $204 +12% |
| Stifel | 86 % | +54.7 % | 7 | — |
| Stephens & Co. | 40 % | +10.5 % | 5 | — |
| SVB Leerink | 29 % | -1.2 % | 7 | — |
| Keybanc | 43 % | -5.4 % | 7 | — |
✅ Reasons to believe
- 89% of analysts rate it a buy (Buy consensus, 9 ratings) — a sign of market conviction.
⚠️ Reasons to hesitate
- Even the most reliable firm on RGEN, Jefferies (80% hit rate, 5 scored calls), only targets $135 (call made on September 12, 2025, maturing on September 12, 2026) (-26%) in its most recent call. The stock may already have run past its target.
- The consensus is not unanimous: of 9 ratings, 1 is neutral.
- Limited upside: the median target is only -12% from the current price.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on RGEN
Median target $160 (-12%) · 9 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Repligen now?
We won't decide for you. The facts: 89% of analysts rate it a buy, median target $160 (-12%), and Jefferies (most reliable on RGEN, 80%) targets $135. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Repligen?
The stated upside is small: the median target ($160) sits just -12% from the price ($182) (most reliable on RGEN: Jefferies, 80%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Repligen still worth investing in?
It depends on the gap between the price ($182) and its estimated value: analysts target $160 on median (-12%), with 89% buys (most reliable on RGEN: Jefferies, 80%). Cross-check with their real reliability on RGEN and the cautions above. Information, not advice.
What's the main risk in buying RGEN?
Even the most reliable firm on RGEN, Jefferies (80% hit rate, 5 scored calls), only targets $135 (call made on September 12, 2025, maturing on September 12, 2026) (-26%) in its most recent call. The stock may already have run past its target.
→ Go deeper: the full Repligen profile (consensus, analyst reliability, price target, performance).